Merck's Q1 Earnings: Keytruda's Performance to Shape Pharma's Run

Mercks first quarter earnings, set to be released this Thursday, are under scrutiny. Analysts predict a 1.9% year-over-year revenue increase, contrasting last years 1.6% drop. Last quarter, Merck exceeded revenue forecasts with a 5% jump, but missed full-year earnings projections. Pharma stocks have surged, but Mercks shares have lagged, dropping 6.7% over the past month. As the first major pharma company to report, Mercks performance will set the tone for the industry. Investors are eager to see if Keytruda and other blockbusters can drive a rebound. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/454444f4915e9033